Lifecare reaches regulatory milestone - veterinary product cleared for sales in Europe

26 Feb 2026 07:00 CET

Bergen, Norway, 26 February 2026 -- Lifecare ASA (LIFE), a MedTech company
developing next-generation implantable Continuous Glucose Monitoring (CGM)
technology, announces that it has reached a key regulatory milestone: the
electronics used in its implant system are now CE marked under applicable
European directives.

Following completion of the conformity assessment process and signing of the
EU Declaration of Conformity, the electronics module has formally achieved CE
marking under the applicable EMC and Radio Equipment directives, based on
completed compliance testing and finalized technical documentation.

As a result, the veterinary product containing these electronics is CE marked
under applicable EU product legislation and cleared for commercial sales in
Europe.

The CE marked electronics are already in use in the Company's reproducible
production batch and longevity study implants and will be used in the upcoming
First-in-Human study.

Electronics used in implantable medical devices are subject to rigorous safety
and reliability requirements. Unlike external devices, implant electronics
must operate safely inside the body over extended periods without posing
electrical, thermal, or electromagnetic risk.

"The CE marking of our electronics represents a significant regulatory
milestone," says Joacim Holter, CEO of Lifecare ASA. "It confirms that the
core active component of our implant platform meets stringent European safety
and performance requirements in a production-level configuration. This
materially strengthens our regulatory foundation ahead of veterinary
commercialization and clinical progression. With this milestone achieved, we
are now well positioned to establish strategic partnerships for sales and
distribution in the veterinary market."

The CE marking announced today relates specifically to the electronics module
under applicable EU directives, namely EMC and Radio Equipment directives, and
veterinary commercial use. Lifecare will continue to progress towards
regulatory compliance for human use, in line with previously communicated
development plans.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2026-02-26 07:00
CET.

More information:
Access the news on Oslo Bors NewsWeb site

666853_Lifecare reaches regulatory milestone - veterinary product cleared for sales in Europe.pdf